A once-in-a-century global pandemic has reinforced the value of the scientific advances America’s innovative and indispensable biopharmaceutical industry makes possible.
The breakthroughs in vaccine research and therapeutics to combat COVID-19 are built on a collaborative ecosystem that drives scientific discovery.
As Americans get vaccinated and we start to recover from this crisis, we need to build on what we’ve learned from COVID-19 and other challenges. Our top priority is lowering the barriers between our medical innovations and the patients who need them.
America’s biopharmaceutical industry is ready to do our part. We are willing to work with all stakeholders to deliver a stronger, more resilient, affordable, and equitable health care system for all.
Common-sense, patient-centered reforms built on three core goals will help ensure everyone benefits from America’s engine of innovation and gets the care they need and deserve: